Advertisement

Clinical Scenario: Persistent CIS and High-Grade Ta Bladder Cancer After BCG

Clinical history: 79-Year-old man who has a persistent CIS despite induction and maintenance BCG for 6 months
  • Maurizio BrausiEmail author
Chapter

Abstract

The standard treatment for Ta-T1 high-grade (G3) TCC of the bladder and CIS is TUR followed by BCG full dose once a week for 6 weeks and then at month 3, 6, 12, 18, 24, 30, 36 according to the SWOG schedule.

The efficacy of adjuvant immunotherapy in the elderly has been discussed and questioned. A reduced activity of BCG has been reported due to the impairment of the immune-system response than in patients more than 75 years of age.

When a patient with CIS presents with a recurrence during BCG therapy it can be called BCG failure. The therapy of patients with CIS who experienced a BCG failure is radical cystectomy, according to international guidelines. However, in elderly patients with co-morbidities unfit or refusing surgery a conservative treatment can be adopted.

Chemotherapy with MMC and hyperthermia (Synergo) once a week for 6 weeks should be the first choice. A second option for these patients with recurrent CIS is the administration of Gemcitabine high dose (2,000 mg a week) for 6 weeks.

Finally, INF-alfa with BCG has shown efficacy in these patients.

Keywords

Recurrent carcinoma in situ Elderly BCG failure Alternative treatments 

References

  1. 1.
    Morales A, Edinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J Urol. 1976;116(2):180–3.PubMedGoogle Scholar
  2. 2.
    Brosman SA. Experience with Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1982;128(1):27–30.PubMedGoogle Scholar
  3. 3.
    Lamm DL, Blumenstein BA, Cristmann JD, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta-T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169: 90–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174:86–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? a meta- analysis of randomized trials. Urology. 2006;67:1216–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long term outcome of randomized studies comparing intravesical Mitomycin C versus bacillus Calmette-Guerin for non muscle invasive bladder cancer. Eur Urol. 2009;56:247–56.PubMedCrossRefGoogle Scholar
  9. 9.
    Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC Genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus Isoniazid in patients with intermediate and high-risk stage TaT1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(Suppl):766–70. 715–34.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Lamm DL, Persad R, Colombel M, et al. Maintenance bacillus Calmette-Guérin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2010;9(Suppl):715–34.CrossRefGoogle Scholar
  11. 11.
    Brausi M, Witjes A, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of non-muscle invasive bladder cancer by the international bladder cancer group. J Urol. 2011;186:2158–67.PubMedCrossRefGoogle Scholar
  12. 12.
    Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillis Calmette-Guérin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462–72.PubMedCrossRefGoogle Scholar
  13. 13.
    Shariat S, Milowsky M, Droller M. Bladder cancer in the elderly. Urol Oncol. 2009;27:653–67.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Shariat S, Sfakianos J, Droller M, et al. The effect of age and gender on bladder cancer: a critical review of the literature. BJUI. 2009;105:300–8.CrossRefGoogle Scholar
  15. 15.
    Herr H. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urology. 2007;70(1):65–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Joudi F, Smith B, O’Donnell A, et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175:1634–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Heiner J, Terris M. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. Urol Oncol. 2008;26:137–40.PubMedCrossRefGoogle Scholar
  18. 18.
    Babjuk M, Oosterlinck W, Sylvester R et al. European Association of Urology guidelines on TaT1 non muscle invasive bladder cancer. Update march 2009. Arnhem, The Netherlands: European Association of Urology; 2009. Available from http://www.uroweb.org/professional-resources/guidelines/online.
  19. 19.
    Lamm D, Colombel M, Persad R, et al. Clinical recommendations for the management of non-muscle invasive bladder cancer. Eur Urol. 2008;7(Suppl):651–66.CrossRefGoogle Scholar
  20. 20.
    Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology. 2005;66(Suppl 6A):108–25.PubMedCrossRefGoogle Scholar
  21. 21.
    O’Donnell M. Optimizing BCG, therapy. Urol Onc. 2009;27:325–8.CrossRefGoogle Scholar
  22. 22.
    Yates D, Brausi M, Catto J, et al. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Eur Urol. 2012;62: 1088–96.PubMedCrossRefGoogle Scholar
  23. 23.
    Lammers RJM, Witjes JA, Innam BA, et al. The role of combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle invasive bladder cancer: a systematic review. Eur Urol. 2011;60:81–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Urology Ausl ModenaB. Ramazzini HospitalCarpi-ModenaItaly

Personalised recommendations